The stable knockdown of FOXM1 in AML cells lines KG-1 and MV4-11 results in increased sensitivity to cytarabine, the backbone for the initial treatment of AMLs together with an anthracycline. This evidence concerns the gene FOXM1 and acute myeloid leukemia.